Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.87 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.87 |
| ▸ | PREP | P48147 | 4/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910608 | 1.00 | CHRM2 (0.87) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL910610 | 1.00 | CHRM2 (0.87) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL31080439 | 1.00 | CHRM2 (0.87) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL219188 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL22433392 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL19082743 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL641026 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL20636193 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL10106331 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPKAT2B | |
| SCHEMBL1023170 | 0.93 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934212-B1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | MSD OSS BV (NL) | 2013-02-20 | — | — | EP | disclosed |
| EP-1934212-B1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | MSD OSS BV (NL) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011021645-A1 | BICYCLIC UREA DERIVATIVE OR PHARMACOLOGICALLY PERMITTED SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| EP-1934212-A1 | 9-AZABICYCLO [3 . 3 . 1]NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. Organon (NL) | 2008-06-25 | — | — | EP | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039563-A1 | 9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS | N.V. ORGANON (NL) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | AZI2, TPMT, TET3 | CHRM2 1569/4885CHRM1 1450/4885CHRM3 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.